What is flibanserin used for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Flibanserin Used For?

Flibanserin is FDA-approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. 1

Primary Indication

Flibanserin is specifically indicated for premenopausal women experiencing:

  • Acquired HSDD: Low sexual desire that developed in women who previously had no problems with sexual desire
  • Generalized HSDD: Low desire that is not limited to certain types of stimulation, situations, or partners
  • Duration: Symptoms present for at least 6 months that cause marked distress 1, 2

Mechanism and Dosing

Flibanserin works as a 5-HT1A receptor agonist and 5-HT2A receptor antagonist, modulating neurotransmitters involved in sexual desire. The approved dose is 100 mg taken once daily at bedtime 1, 2.

Clinical Context and Efficacy

The drug demonstrates statistically significant but modest clinical benefits. In pooled analyses of pivotal trials involving 2,465 premenopausal women, flibanserin showed 2:

  • Increase of approximately 0.5-1 additional satisfying sexual event per month compared to placebo
  • Improvements in sexual desire scores and reduction in distress related to low desire
  • Benefits generally consistent across various demographic subgroups

Use in Cancer Survivors

ASCO guidelines (2018) state that clinicians may offer flibanserin to premenopausal women with HSDD, though with important caveats 3:

  • Flibanserin has not been evaluated in women with a history of cancer or those on endocrine therapy
  • The risk/benefit ratio remains uncertain in this population
  • Psychosocial/psychosexual counseling should be offered as first-line intervention

Important Safety Considerations

Common adverse effects occur significantly more frequently than placebo 4:

  • Dizziness (4-fold increased risk)
  • Somnolence (4-fold increased risk)
  • Nausea (2.4-fold increased risk)
  • Fatigue (1.6-fold increased risk)

Critical contraindications and warnings 1:

  • Absolute contraindication with alcohol due to risk of severe hypotension and syncope
  • Contraindicated with moderate-to-strong CYP3A4 inhibitors
  • Must be taken at bedtime to minimize sedation-related risks
  • Requires daily dosing (not taken "as needed")

Clinical Perspective

The FDA approval in 2015 remains somewhat controversial 5, 4. The quality of evidence is graded as "very low," and the clinical significance of the modest improvements must be weighed against the substantial adverse effect profile. Women's global impression of improvement scores indicated only "minimal improvement to no change" 4.

Flibanserin is not approved for postmenopausal women, though some research suggests potential benefit in this population 6. It is also not indicated or approved for use in men 7.

Practical Application

Before prescribing flibanserin:

  • Confirm diagnosis of acquired, generalized HSDD of ≥6 months duration
  • Rule out other causes of low desire (relationship issues, medications, medical conditions, depression)
  • Discuss realistic expectations: approximately one additional satisfying sexual event per month
  • Counsel on adverse effects, particularly sedation and dizziness
  • Emphasize absolute alcohol avoidance
  • Consider psychosocial counseling as first-line or adjunctive therapy
  • Recognize this requires long-term daily use (potentially years) for sustained benefit 8

Related Questions

What are the current indications, dosing recommendations, and safety considerations for Addyi (flibanserin)?
What is Addyi (flibanserin) and how is it used to treat hypoactive sexual desire disorder in premenopausal women?
Can Flibanserin (Addyi) be safely sold by a pharmacy like Mercury Drug?
Is Flibanserin (Addyi) approved for use in men?
What 5‑HT2A antagonists are appropriate for a premenopausal woman with acquired generalized hypoactive sexual desire disorder, and what are their dosing and safety considerations?
In a 63‑year‑old woman with relapsed/refractory IgG‑kappa multiple myeloma after B‑cell maturation antigen (BCMA) chimeric antigen receptor T‑cell (CAR‑T) therapy, chronic severe thrombocytopenia (platelets ~22 K despite romiplostim and transfusions), low‑level cytomegalovirus (CMV) and human herpesvirus‑6 (HHV‑6) viremia, and five new punctate enhancing brain lesions on MRI, what additional hematology/oncology workup or management should be pursued to distinguish central nervous system myeloma relapse from opportunistic infection, how can cerebrospinal fluid be obtained safely given persistent thrombocytopenia, and should further systemic myeloma restaging be performed?
In an 87‑year‑old woman with recent right‑rib fractures, resolved mild pneumonia, new left‑sided chest pain after a second fall, dizziness, low‑grade oxygen desaturation, and fatigue, how should the ordered laboratory results (complete blood count, basic metabolic panel, inflammatory markers, arterial blood gas or pulse oximetry, and coagulation profile) be interpreted and managed?
What is the recommended management of diabetes in a patient with coronary artery disease?
What is the significance and recommended management of ST‑segment depression in ECG leads V1 to V3?
In a stable 15‑year‑old boy with massive left primary spontaneous pneumothorax and persistent mediastinal shift after three therapeutic needle aspirations (approximately 5 L of air removed), what is the most likely cause of the lung's failure to re‑expand, and should an intercostal chest tube be inserted now rather than continued observation with a non‑rebreather mask?
What dose of hyaluronidase is appropriate to dissolve a hyaluronic‑acid filler migration?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.